Scynexis stock jumps 10% after securing BARDA contract worth up to $214 million
Scynexis shares rose 10% in premarket trading after securing a BARDA contract worth up to $214 million for its antifungal treatment SCY-247. The initial funding of $18.5 million will support Phase 2 trials for invasive candidiasis. The contract could span 10 years, with additional funding contingent on progress.
How this was made
The 30-second read
Why it matters
The $18.5 M upfront payment de‑risks the Phase 2 study, likely prompting short‑term buying interest and supporting the stock's recent rally.
Market read
First‑report of a sizable BARDA contract for a micro‑cap biotech, generating a notable price move.
What to watch
Potential dilution if additional capital is needed beyond BARDA support; execution risk of Phase 2 trial.
Background
Scynexis (NASDAQ: SCYX) is a small‑cap biotech developing antifungal candidates. BARDA contracts are rare and provide non‑dilutive capital for clinical advancement.
Ticker impact
Scynexis announced a BARDA contract worth up to $214 million, triggering a ~10% pre‑market price jump.
likely upward pressure as investors price in the initial $18.5 M funding and future upside.
The contract provides immediate cash for Phase 2 and a large conditional upside, reducing dilution risk and supporting the pipeline.
Market effects
Boosts sentiment for biotech firms pursuing BARDA or other government contracts.
Minor impact on US biotech sector; no broader regional effect.
Limited to investors focused on small‑cap biotech and government‑funded drug development.
Counterpoint
Funding is conditional; if later options are not exercised, the stock may face pressure.
Key entities
- companyScynexis
Biotech developer of SCY‑247 antifungal candidate.
- government_agencyBARDA
U.S. Biomedical Advanced Research and Development Authority providing contract funding.